Rh Pharmaceuticals Inc.
In 1983, a new state-of-the-art facility was opened with the capacity to fractionate large volumes of plasma into pharmaceutical products. In 1990, the organization was reorganized as Rh Pharmaceuticals Inc. and we began to expand our involvement in contract manufacturing to augment our own production requirements.
In April 1993, we were licensed by the Health Protection Branch (HPB) to sell our new presentation of WinRho SD in Canada. By adding a solvent detergent treatment step during our manufacturing process, we are able to inactivate viruses such as HIV and Hepatitis B and C, making Rh Pharmaceuticals Inc. one of the first companies in the world to use this inactivation treatment for a product in this category.
We plan to expand our production capacity dramatically by the end of 1993 and expect to commence sale of WinRho SD in the United States in 1994. Internationally, we are selling WinRho SD in Canada, South America, Europe and the Middle East. Our products and technology have captured international attention -- requests for information about WinRho SD and our unique manufacturing process are received from all over the world. In addition, we recently signed an agreement with a large Japanese company to custom manufacture a new pharmaceutical entity.
In conjunction with our parent company, Apotex Inc. of Toronto, we are actively working on pharmaceuticals in the areas of cancer, HIV, asthma and other biotechnology products.
Rh Pharmaceuticals is committed to delivering pharmaceuticals that meet the highest standards of the industry, and looks forward to helping establish a thriving biopharmaceutical industry in Manitoba.